• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

SAPHYR Trial: Sarilumab’s Impact on Refractory Polymyalgia Rheumatica


Robert Spiera, M.D., discusses the SAPHYR trial, assessing sarilumab’s efficacy in treating refractory polymyalgia rheumatica.

This is a video synopsis/summary of a Between the Lines involving Robert Spiera, M.D., and Dana McCormick, R.Ph.

Dana McCormick, R.Ph., and Robert Spiera, M.D., discuss the SAPHYR trial evaluating sarilumab for polymyalgia rheumatica. Focused on steroid-sparing efficacy, the trial targeted tough-to-treat patients, aiming for sustained remission over a year. The study, utilizing sarilumab, involved rapid steroid tapering and a placebo group on a standard taper. The goal was sustained remission by week 52, with stringent criteria including C-reactive protein normalization and no flares post week 14. Secondary outcomes included glucocorticoid dose, flare time and safety. Patient-reported quality-of-life assessments were crucial for this lesser-known disorder, aiding differentiation from other inflammations. Understanding the trial’s design and outcomes sheds light on sarilumab’s potential as a significant therapy. Such insights into effective treatments are vital for optimizing care and improving the lives of patients with polymyalgia rheumatica, a condition often misconstrued among inflammatory diseases.

This summary was AI-generated and reviewed by Managed Healthcare Executive® staff.

Related Videos
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
Video 5 - "FDA Approval Pathway for Prescription Digital Therapeutics"
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
Video 3 - "Harnessing Prescription Drug Therapeutics as Monotherapy and Adjunct Therapy"
Video 8 - "Demographic Differences That Impact Care"
Video 7 - "Gaps in Diabetes Education and Self Efficacy"
Video 6 - "Developing Reimbursement Models for Digital Therapeutics"
Related Content
© 2024 MJH Life Sciences

All rights reserved.